Table 1.

H₂S-releasing drugs as potential anti-inflammatory drugs in arthritis.

H2S-Derivative Drug	Drug	Company	Clinical Phase	Clinical Applications	References
AVT-18A	Sulindac	Avicenna T.	Preclinical	Cancer, inflammation	[144]
NBS-1120	Aspirin	Avicenna T.	Preclinical	Cancer, inflammation	[145]
ACS-14	Aspirin	CTG Ph.	Preclinical	Inflammation, cardiac injury, Arthritis	[150]
ACS-21	Aspirin	CTG Ph.	Preclinical	Inflammation, cardiac injury, Osteoarthritis	[150]
ACS-6	Ketorolac	CTG Ph.	Preclinical	Arthritis Antioxidant	[150,151]
ATB-337/ACS-15	Diclofenac	Antibe T.	Preclinical	Arthritis, inflammation	[150]
ATB-343	Naproxen	Antibe T.	Preclinical	Inflammatory diseases, Alzheimer’s disease	[150]
ATB-346	Naproxen	Antibe T.	Phase II	Osteoarthritis, inflammation	[102,142,150]
ATB-345	Naproxen	Antibe T.	Preclinical	Inflammatory diseases	[102]
ATB-429	Meselamine	Antibe T.	Preclinical	Cancer, inflammatory diseases, colitis	[75]
GYY4137		National Uni. of Singapore	Preclinical	Inflammatory diseases, cancer, hypertension, arthritis	[82,107,123,152]
DAS/DADS			Preclinical	Cancer, arthritis	[148,149]